— Know what they know.
Not Investment Advice

Financial News

Sentiment 46.5 5065 articles 2686 bullish 1112 bearish Full Index →
Can AI Make Home Loans Cheaper? Palantir Thinks So

Can AI Make Home Loans Cheaper? Palantir Thinks So

Palantir Technologies Inc. (NASDAQ:PLTR) and Moder on Thursday announced a strategic partnership to develop an AI-powered mortgage operations...
Super Micro Stock Sees Momentum Score Dip Despite Partner Nv

Super Micro Stock Sees Momentum Score Dip Despite Partner Nvidia's Launch Of New Blackwell AI Chips

Shares of Super Micro Computer Inc. (NASDAQ:SMCI) are facing a stark divergence between its operational milestones and its stock market performance...
ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?

ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?

AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?

ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?

AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?

ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?

AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
Why Are Micron Technology Shares Trading Lower On Thursday?

Why Are Micron Technology Shares Trading Lower On Thursday?

Micron Technology Inc (NASDAQ:MU) shares are down during pre-market trading on Thursday after the company delivered its second-quarter results on...
Castlemead Joins TechAssure's Select Global Network of Speci

Castlemead Joins TechAssure's Select Global Network of Specialist Brokers

WASHINGTON, March 19, 2026 /PRNewswire/ -- TechAssure, the international network of insurance brokers specializing in complex and emerging risks, has...
📰

After the Viewbix-Quantum X Labs Closing: 5 Nasdaq Quantum Stocks to Watch

Moonage Media reviews the emerging quantum sector in the capital markets following Viewbix's acquisition of Quantum X Labs HONG KONG, March 19, 2026...
📰

Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing...
📰

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage...
📰

Sarepta pushes 2 Duchenne drugs toward traditional approval after mixed data - Stock Titan

Sarepta pushes 2 Duchenne drugs toward traditional approval after mixed data  Stock Titan
Prologis and GIC Form $1.6 billion U.S. Build-to-Suit Logist

Prologis and GIC Form $1.6 billion U.S. Build-to-Suit Logistics Joint Venture

Partnership to Fund Build-to-Suit Distribution Projects Across Major U.S. Markets SAN FRANCISCO and SINGAPORE, March 19, 2026 /PRNewswire/ --...
📰

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Y

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to...
📰

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key...
📰

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

<ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml"><i...
📰

Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients

Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
📰

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

CAMBRIDGE, Mass., March 19, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today...
📰

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key...
📰

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p...
110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC

110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC Bancorp USA Inc.

CIBC Bancorp USA Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company...
110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC

110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC Bancorp USA Inc.

CIBC Bancorp USA Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company...
110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC

110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC Bancorp USA Inc.

CIBC Bancorp USA Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company...
Accenture Stock Hits 52-Week Low - Here's Why

Accenture Stock Hits 52-Week Low - Here's Why

Accenture plc (NYSE:ACN) shares fell Thursday after the company's fiscal second-quarter 2026 results, as a cautious outlook overshadowed an...
Johnson & Johnson-Protagonist Therapeutics Partnered New Pso

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for...
Johnson & Johnson-Protagonist Therapeutics Partnered New Pso

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for...
Johnson & Johnson-Protagonist Therapeutics Partnered New Pso

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for...
📰

Aveanna Healthcare (AVAH) Beats Q4 Earnings and Revenue Estimates

Aveanna (AVAH) delivered earnings and revenue surprises of +38.78% and +5.64%, respectively, for the quarter ended December 2025. Do the numbers hold...
📰

Aveanna Healthcare (AVAH) Beats Q4 Earnings and Revenue Estimates

Aveanna (AVAH) delivered earnings and revenue surprises of +38.78% and +5.64%, respectively, for the quarter ended December 2025. Do the numbers hold...
CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER

CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER

Upon the 2026 Stockholders' Meeting to be held in May 2026, subject to approval by the stockholders and board of directors of the Company, Corvex...
📰

CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER

Upon the 2026 Stockholders' Meeting to be held in May 2026, subject to approval by the stockholders and board of directors of the Company, Corvex...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Sessio

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Mi

Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were slightly lower this morning, with the S&P 5000 futures falling around 0.1% on Thursday. Shares of Alibaba Group Holding...
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Mi

Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were slightly lower this morning, with the S&P 5000 futures falling around 0.1% on Thursday. Shares of Alibaba Group Holding...
Aerolínea brasileña GOL lanza venta de pasajes para vuelos i

Aerolínea brasileña GOL lanza venta de pasajes para vuelos intercontinentales directos entre Brasil y Portugal"

SÃO PAULO, 19 de marzo de 2026 /PRNewswire/ -- La aerolínea brasileña GOL Linhas Aéreas, que ahora inicia su fase intercontinental tras el reciente...

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms